Nephrogenic diabetes insipidus. Effects of 3,5, cyclic-adenosine monophosphate.
D000293:Adolescent; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D003404:Creatinine / Q000652:urine; D000242:Cyclic AMP / Q000008:administration & dosage / Q000627:therapeutic use*; D003919:Diabetes Insipidus / Q000188:drug therapy*; D005919:Glomerular Filtration Rate; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007684:Kidney Tubules / Q000002:abnormalities*; D009994:Osmolar Concentration; D012964:Sodium / Q000652:urine; D014508:Urea / Q000652:urine; D014556:Urine; D014667:Vasopressins / Q000627:therapeutic use
D014667:Vasopressins; D014508:Urea; D012964:Sodium; D003404:Creatinine; D000242:Cyclic AMP